Placebo + VK2735

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Weight Loss

Conditions

Weight Loss

Trial Timeline

Dec 18, 2024 → Aug 15, 2025

About Placebo + VK2735

Placebo + VK2735 is a phase 2 stage product being developed by Viking Therapeutics for Weight Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT06828055. Target conditions include Weight Loss.

What happened to similar drugs?

4 of 20 similar drugs in Weight Loss were approved

Approved (4) Terminated (1) Active (15)
Exenatide + PlaceboEli LillyApproved
olanzapineEli LillyApproved
AripiprazoleBristol Myers SquibbApproved
🔄VK2735Viking TherapeuticsPhase 3
🔄VK2735Viking TherapeuticsPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06828055Phase 2Completed

Competing Products

20 competing products in Weight Loss

See all competitors